EMD

EMYRIAL FPO [EMD]
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.
Healthcare · ASX Small Cap
$0.0480 -2.0%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when EMD triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track EMD — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Pressing against the upper Bollinger Band — extended and may need to cool off
  • Trading above both moving averages — the trend is your friend here
  • Volume surging at 2.0x normal while price falls — heavy selling pressure
  • On a tear — up 23.1% over the last 5 days
  • Beating the Small Ords index — relative strength of 1.32, so it's outpacing the pack
  • Strong cash runway (11 quarters)
  • Strong revenue growth (+136%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +136% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (0.57%/day)
  • Low-priced stock risk ($0.049)
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 8d (+5pts)

Risk Signals

  • Stochastic is stretched into overbought — could need a breather
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-199%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 33% over the past year
Ask Scout AI about EMD
"What's driving EMD today?" "How does EMD compare to peers?" "Key risks for EMD?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Emyria to Present at Upcoming Investor and Industry Events
NONE Emyria Confirms NSW Workforce Ahead of Clinic Opening
HIGH Emyria Depression Program Shows Positive Results
LOW Emyria Company Update - Video Presentation
LOW Emyria Company Update Presentation

Recent ASX Announcements

2026-07-15 Emyria to Present at Upcoming Investor and Industry Events
2026-06-23 Emyria Depression Program Shows Positive Results PRICE SENSITIVE
2026-06-21 Emyria Confirms NSW Workforce Ahead of Clinic Opening PRICE SENSITIVE
2026-06-15 Emyria Company Update - Video Presentation
2026-06-10 Emyria Company Update Presentation PRICE SENSITIVE

Key Metrics

$39.5M
Market Cap
1.0M
Avg Volume
2.0x
Vol Ratio
$0.03 — $0.08
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-58.6%
ROE
-198.5%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 73%
LLeader vs LaggardlaggardRS: -3
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:EMD vs ECSEMD vs VHLEMD vs NTI
Scout Pro — Deeper Analysis for EMD
Try Pro free for 30 days
Share this analysis

Track EMD and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required